248 related articles for article (PubMed ID: 12911317)
21. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
[TBL] [Abstract][Full Text] [Related]
22. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
23. Locking the ATP-operated clamp of DNA gyrase: probing the mechanism of strand passage.
Williams NL; Howells AJ; Maxwell A
J Mol Biol; 2001 Mar; 306(5):969-84. PubMed ID: 11237612
[TBL] [Abstract][Full Text] [Related]
24. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
26. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
van Hille B; Clerc X; Creighton AM; Hill BT
Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
[TBL] [Abstract][Full Text] [Related]
28. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
[TBL] [Abstract][Full Text] [Related]
29. Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Renodon-Cornière A; Sørensen TK; Jensen PB; Nitiss JL; Søkilde B; Sehested M; Jensen LH
Mol Pharmacol; 2003 May; 63(5):1159-68. PubMed ID: 12695544
[TBL] [Abstract][Full Text] [Related]
30. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
[TBL] [Abstract][Full Text] [Related]
31. Intradimerically tethered DNA topoisomerase II is catalytically active in DNA transport.
Lindsley JE
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2975-80. PubMed ID: 8610153
[TBL] [Abstract][Full Text] [Related]
32. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
33. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187.
Classen S; Olland S; Berger JM
Proc Natl Acad Sci U S A; 2003 Sep; 100(19):10629-34. PubMed ID: 12963818
[TBL] [Abstract][Full Text] [Related]
34. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
35. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
36. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 1. A DNA-dependent burst in ATP hydrolysis.
Harkins TT; Lindsley JE
Biochemistry; 1998 May; 37(20):7292-8. PubMed ID: 9585543
[TBL] [Abstract][Full Text] [Related]
37. The ATP-operated clamp of human DNA topoisomerase IIalpha: hyperstimulation of ATPase by "piggy-back" binding.
Campbell S; Maxwell A
J Mol Biol; 2002 Jul; 320(2):171-88. PubMed ID: 12079377
[TBL] [Abstract][Full Text] [Related]
38. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.
Gilroy KL; Leontiou C; Padget K; Lakey JH; Austin CA
Nucleic Acids Res; 2006; 34(5):1597-607. PubMed ID: 16549872
[TBL] [Abstract][Full Text] [Related]
39. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex.
Jayaraju D; Gopal YN; Kondapi AK
Arch Biochem Biophys; 1999 Sep; 369(1):68-77. PubMed ID: 10462441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]